Aim. The work is devoted to the development of less invasive tools for the colorectal cancer (CRC) screening.
Introduction. Colorectal cancer (CRC) is the third commonly diagnosed cancer that causes more than 600 000 deaths per year worldwide [1] . In most cases, CRC tumors grow slowly -approximately 1 cm per year without noticeable symptoms. The most sensitive modern diagnostic tool for the CRC detection is a colonoscopy. It allows detecting the tumors of less than 1 cm. However, the colonoscopy procedure is painful and in some cases is not recommended to the patients with heart diseases, because of possible adverse cardiopulmonary reactions that are usually related to the sedation [2] as the colonoscopy is performed under narcosis. Also, the colonoscopy meets some difficulties in case of altered topography of a colon [3] . Thus, the development of less invasive tools for screening CRC is a relevant problem of the modern oncology.
DNA methylation is a stable epigenetic mark which is associated with gene silencing in the case of promoter localization in CpG-island [4] . The gene hypermethylation frequently targets the potential tumor-suppressor genes (TSG), inactivation of which promotes the tumor development. According to Toyota et al., the colon cancer can be ascribed to the tumors with a high frequency of gene hypermethylation. Approximately 17 % of CpG-islands are hypermethylated in CRC [5] .
The circulating cancer cells and cell-free DNA (cf DNA) are frequently detected in the patients with different types of the malignant disease. Moreover, a level of cfDNA is elevated in the cancer patients in comparison with the healthy individuals [6] .
In the proposed paper DNA hypermethylation of the well-known tumor associated genes like LRRC3B, FHIT, APC and HIC1 was detected by methylationspecific PCR (MSP) in the plasma and tumor samples from the CRC patients [7] [8] [9] [10] . Adjacent to the tumor non-malignant tissues of bowel were used as a control. Additionally, the levels of cfDNA in plasma from the CRC patients and healthy donors were mesuared by quantitative PCR (Q-PCR). All experiments were carried out with the tumors, adjacent non-malignant tissues and plasma samples of the same patients.
Material and methods. Ethics statements. The samples were collected in accordance with the Declaration of Helsinki and approved by the guidelines issued by the Ethic Committee of the National Cancer Institute of the Academy of Medical Sciences, Kyiv, Ukraine.
Sample collection, genomic and cell-free DNA isolation. Twenty surgically excised tissue samples of CRC were used in the present study (Table 1 ). All tumor samples were paired with non-malignant tissues, which were taken as the normal tissue samples. Immediately after surgery, the tissue samples were frozen in liquid nitrogen and stored at -70 o C. Neither chemotherapy nor radiotherapy was conducted for any patients prior to surgery. Each tissue sample was accompanied by a corresponding blood sample. All tissue samples were characterized histologically. Blood of 21 healthy donors was used as a control group.
Genomic DNA was purified by GenElute Mammalian Genomic DNA Miniprep Kit («Sigma-Aldrich», USA) according to the manufacturer's recommendations. Briefly, 50 mg of tissue were homogenized in liquid nitrogen, subjected to lysis and purified with GenElute Miniprep Binding Columns. The quality and size of genomic DNA were assessed by gel electrophoresis («Sigma-Aldrich»).
Plasma from the cancer patients and the healthy donors was obtained by the multistage centrifugation of the blood in range from 1000 to 3000 g, using EDTA as an anticoagulant. The cell free circulating DNA from 200 ml of plasma was isolated by the Proba NK DNA («DNA Technology», Russia) isolation kit, according to the manufacturer's instructions.
Determination of concentrations of cell free DNA. To detect the concentration of cell free circulating DNA in the plasma, the Q-PCR was used. The Q-PCR was performed with SYBR Green mixture («Thermo Scientific», USA) and primers for the GAPDH gene: gRef nomic DNA was performed, using the EZ DNA Methylation kit («ZYMO Research», USA), according to the manufacturer's protocol. For the bisulfite treatment of the plasma DNA 44 ml of solution of the dissolved DNA sediments with co-precipitator were used. To protect the plasma DNA during the reaction, 450 ng of Lambda DNA were added per a reaction sample of bisulfite treatment.The bisulfite treated DNA was dissolved in 20 ml of Elution buffer.
To determine the methylation status of the LRRC3B, APC, FHIT, and HIC1 genes in tissue samples, the methylation-specific PCR (MSP) was used. MSP was performed using primers that were described previously [11] [12] [13] [14] . Amplification of the bisulfite converted sequence of the COL2A1 gene was used as a control of the DNA input [14] . The PCR mixture of MSP reactions contained 10´PCR Dream buffer («Thermo Scientific»), 0. cycles. The quality of amplified products was checked by electrophoresis in 2.5 % agarose gel and melting curve analysis with the CFX real-time PCR detection system («BioRad»). To verify RT-MSP data, the MSP sequencing assay was performed.
Statistical analysis. Statistical analysis was performed using STATISTICA 7.0 program («StatSoft Inc», USA). If the p-value was < 0.05 the results were considered statistically significant. The nonparametric MannWhitney U Test was used to calculate the difference between concentration of plasma cfDNA in CRC patients and healthy donors.
Results and discussion. The levels of cell free circulating DNA in the plasma from CRC patients are higher than in healthy donors. Using Q-PCR, the level of cell free circulating DNA was determined in the plasma of CRC patients and healthy donors (Table 1, Figure) . It was shown that the mean value of concentration of plasma cfDNA was significantly higher in CRC patients, compared with the healthy donors (p < 0.01). Thus, the mean value (MV) of concentration of cell-free circulating DNA in the plasma from CRC patients was 29.45 ± 12.24 ng/ml (MV ± St. Error), whereas it was 7.07 ± 0.82 (MV ± St. Error) in healthy donors. In order to generate the upper cut-off value of the cell free circulating DNA concentration in plasma we used the highest permissible concentration in the healthy donors. It was defined as a mean value concentration of cfDNA of healthy donors and three standard deviations. So, the upper cut-off value of the free-circulating DNA concentration was 17.7 ng/ml of the plasma in healthy donors (Figure) .
Therefore, there were 8 out of 20 samples of CRC which fell into criteria as samples with an abnormally increased DNA level.
Hypermethylation of tumor suppressor genes in the cancer tissues and plasma samples from CRC patients. APC, FHIT, LRRC3B and HIC1 are the colon cancer as- CfDNA concentration in plasma of 20 CRC patients (1) and 19 healthy donors (2) was detected by Q-PCR. The upper cut-off value of the free-circulating DNA concentration of healthy donors is depicted as a dashed line at 17.7 ng/ml level of plasma. To prevent merger of data points one CRC (N 132) concentration was not included here, it equals 252,7 ng/ml sociated genes. Their alterations due to the promoter CpG-island methylation were described previously.
Thus, hypermethylation of APC, FHIT, LRRC3B and HIC1 was detected in 45, 37, 77 and 42 % of CRC samples correspondingly [15] [16] [17] [18] . Therefore, the MSPbased detection of the methylated fragments of these genes was used for further development of screening panel for CRC. In the current research we have found that the APC, FHIT, and LRRC3B genes were hypermethy- N o t e . M -methylated DNA was detected; U -unmethylated DNA was detected; H -cfDNA concentration is higher than upper cut-off value; LcfDNA concentration is lower than upper cut-off value; ND -methylated DNA was not detected; «+» -methylation was detected in one or more genes for the tissue; «-» -no methylation was detected for at least one genes for the tissue; A -abnormal plasma; NC -no changes have been detected in the plasma. No amplification was found in reactions with MSP primers and bisulfite treated Lambda DNA which did not include the human DNA. No methylated fragments of the selected genes were identified in plasma of healthy donors.
Therefore, the hypermethylated fragments of APC, FHIT, and LRRC3B genes in the plasma were detected in 50 % (5/10), 31 % (4/13) and 23 % (3/13) of tumors which were positive for hypermethylated fragments of the abovementioned genes, respectively. To verify specificity of MSP, the PCR products of the APC and LRRC3B genes were sequenced after amplification with the primers for methylated DNA.
To study specificity of the gene panel, hypermethylation of the APC, FHIT and LRRC3B genes was studied in the plasma of healthy donors. Moreover, the methylation of APC, FHIT and LRRC3B in plasma was detected in 92 % (12/13) of the samples with pre-detected methylation of these genes in tumor tissue. Initially we had shown the same tendency in hypermethylation of the APC, FHIT and LRRC3B genes in the plasma of CRC patients [19] .
Additionally, we have registered a high frequency of the HIC1 hypermethylation in the plasma of CRC patients -80 % (8/10). Similar study of the healthy donor's plasma has revealed the hypermethylation of HIC1 at the similar level -80 % (12/15) . No difference in the HIC1 and COL2A1 hypermethylation was observed in CRC patients and healthy donors: mean values of Ct CRC 32.7 -HIC1 and 28.6 -COL2A1 and Ct healthy donors 35.0 -HIC1 and 30.5 -COL2A1.
This indicates a low selectivity of the HIC1 hypermethylation in CRC patients. Therefore, we concluded that the HIC1 hypermethylation is not a valuable marker for the prediction of CRC.
We proposed that a two-stage verification must be applied for CRC screening. These stages include the measurement of the cell-free circulating DNA and the following detection of the methylated fragments of APC, FHIT, and LRRC3B genes in the CRC patient plasma. This allows us to achieve a sensitivity of the panel in CRC detection up to 75 % (Table 2) .
However, our research has not resulted in the sensitivity of 100 % for the CRC registration that is essential for the prevention of this disease. We hope that a higher sensitivity might be achieved by further extension of the gene panel for the identification of methylated DNA in the plasma of CRC patients.
Conclusions. In the present work we have characterized hypermethylation of the APC, FHIT, LRRC3B, and HIC1 genes in the patients with CRC in comparison with the healthy donors. We have found that hypermethylation of the APC, FHIT, and LRRC3B gene fragments in the plasma fully corresponds to hypermethylation of these genes in the tumors.
We have proposed and tested the novel approach for CRC screening, based on the detection of cell-free DNA and methylated fragments of the well-known tumor associated genes, such as APC, FHIT, LRRC3B, and HIC1 in the blood plasma. With such approach 75 % of sensitivity could be achieved. The sensitivity for CRC detection might be increased by the analysis of additional tumor-associated genes.
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